Fungal infection treatments – What you need to know

The significance of fungal infection is often neglected in society. However, fungal infections affect more than a billion people, resulting in approximately 11.5 million life-threatening infections and more than 1.5 million deaths annually.1   The antifungals, used to treat fungal infections, are a diverse group [...]

2019-08-15T10:51:47+00:00August 15th, 2019|

Dave Edwards joins Blueberry Therapeutics

Blueberry Therapeutics are delighted to welcome Dave Edwards as Pharmaceutical Development Director, where he is responsible for CMC aspects of the manufacture of clinical supply materials through Phase II and III studies as well as [...]

2019-07-16T09:28:46+00:00July 1st, 2019|

Diane Lee joins the Blueberry team

We are delighted to welcome Diane Lee to the Blueberry Clinical Team. Diane has over 15 years’ experience in clinical research in different settings; Clinical Research Organisations, pharmaceutical companies and academic research.  She has a [...]

2019-07-03T21:01:54+00:00June 4th, 2019|

The rise of resistant Candida auris – A global issue

Fungal ‘superbug’ drug-resistant Candida auris has been identified by the Centres for Disease Control and Prevention (CDC) as a ‘serious threat to global health’ following a startling increase in the number of infection cases that do not respond to treatment over recent years.   Candida is most notably associated [...]

2019-06-03T12:53:44+00:00June 3rd, 2019|

Fungal Disease – A Global Opportunity for Improved Health in Developing Countries

As the World Health Organization focuses on what universal health coverage means in 2019, we explore the global challenges and opportunities in the control of fungal infection. Although we often think of fungal infection [...]

2019-05-10T15:08:46+00:00May 10th, 2019|

UK-Based Nanomedicine firm set plans to initiate a large phase II efficacy study in 2019

Fungal Nail Infection (Onychomycosis) is the most common nail disorder.1 Risk factors such as trauma, old age, diabetes, immunosuppression, tinea pedis, psoriasis, and family history are leading to an increased prevalence.2 Onychomycosis is characterised by [...]

2019-04-18T14:36:03+00:00April 18th, 2019|

CEO Dr. John Ridden talks Biotech Strategy & Nanomedicine

Blueberry Therapeutics’ CEO, Dr. John Ridden sat down with Pharmaphorum’s Dominic Tyer to talk strategy and bringing innovation to life through Blueberry Therapeutics' nanomedicine approach. Dr. Ridden also spoke about the concept of risk [...]

2019-02-08T13:11:03+00:00February 8th, 2019|

Blueberry Therapeutics wins Bionow’s Company of the Year Award

Alderley Park, UK, 4thDecember 2018– Blueberry Therapeutics won the coveted ‘Company of the Year’ award after another remarkable year of progress and innovation. 2018 has seen many great achievements for Blueberry Therapeutics including the [...]

2018-12-19T08:29:46+00:00December 19th, 2018|

Noria joins Blueberry as a CRA

Blueberry Therapeutics are delighted to welcome Noria Mbuisa to the team! Noria joins us as a Clinical Research Associate, where she leads the review of study regulatory documents and data analysis. Noria has a [...]

2018-12-18T08:31:40+00:00December 10th, 2018|

Blueberry Therapeutics Limited closes £10m funding to support development of nanomedicines portfolio

Alderley Park, UK, 14 August 2018– Blueberry Therapeutics Limited, (“Blueberry Therapeutics”) a drug discovery and development company focused on developing innovative nanomedicines for difficult to treat skin and nail infections, today announces that it [...]

2018-08-14T13:28:49+00:00August 14th, 2018|

CEO attending BIO International, Boston

John Ridden, Blueberry CEO will be attending BIO International convention in Boston, 4th-7th June. 2018 is the 25th year for the BIO Convention, and attracts more than 16,000 biotechnology and pharma leaders who come [...]

2018-06-06T10:59:40+00:00May 29th, 2018|